![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid | |
Other names
AZD-3355 | |
Identifiers | |
| |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
ECHA InfoCard | 100.133.162 ![]() |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C3H9FNO2P | |
Molar mass | 141.082 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABAB receptor agonist,[3] it has the same mechanism of actionasbaclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]
| |
---|---|
H2 antagonists ("-tidine") |
|
Prostaglandins (E)/ analogues ("-prost-") |
|
Proton-pump inhibitors ("-prazole") |
|
Potassium-competitive acid blockers ("-prazan") |
|
Others |
|
Combinations |
|
| |
|
![]() | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |